Evidence map›Paper›PMID 29956132›Full record

ArticleInternational urology and nephrology2018

Serum Arginase II level can be a novel indicator for erectile dysfunction in patients with vasculogenic erectile dysfunction: a comparative study.

Abdel Shakour Abdel Hafez Abdel Wahed, Mohamed Abdel Mawgood Amer, Nagah Mohamed Abou Mohamed, Mohamed Ismael Mobasher, Hassan Mamdouh, Sameh Fayek GamalEl Din, Mohammed Said ElSheemy

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abdel Shakour Abdel Hafez Abdel WahedDermatology & Andrology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Mohamed Abdel Mawgood AmerDermatology & Andrology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Nagah Mohamed Abou MohamedDepartment of Clinical Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Mohamed Ismael MobasherDermatology & Andrology, Ministry of Health, Cairo, Egypt.
Hassan MamdouhDermatology & Andrology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Sameh Fayek GamalEl DinDepartment of Andrology & STDs, Faculty of Medicine, Cairo University, Cairo, Egypt.
Mohammed Said ElSheemyUrology Department, Kasr Al-Ainy Hospitals, Cairo University, Cairo, Egypt. mohammedshemy@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of the study was to compare serum level of Arginase II in patients with vasculogenic erectile dysfunction (ED) versus healthy controls and to assess if its level is affected by severity of ED.

methodsThis is a prospective study that compared Arginase II in 40 patients with ED versus 40 healthy controls. Patients were excluded if they had any pelvic trauma or pelvic surgery, hormonal disorders, Peyronie's disease, smoking, drug addiction or systemic illnesses. ED was evaluated by the validated Arabic version of the abbreviated five-item form of the international index of erectile function (IIEF-5). Serum arginase II level was assayed using ELIZA. Mann-Whitney, Kruskal-Wallis and Chi-square tests and Spearman correlation were used as appropriate and confirmed by logistic regression model.

results22 (55%) patients had DM. 15 (37.5%), 7 (17%), 6 (15%) and 12 (30%) patients suffered from severe, moderate, mild to moderate and mild ED, respectively. The level of serum Arginase II was significantly higher in patients than controls (p < 0.001) and confirmed by multivariate logistic regression analysis. It also correlated significantly with age (r

conclusionSerum level of Arginase II is significantly higher in patients with vasculogenic ED compared to healthy controls. It correlates significantly with age and IIEF-5 and was significantly affected by the severity of ED.

Indexed as

AdultArginaseBiomarkersEnzyme-Linked Immunosorbent AssayFollow-Up StudiesHumansImpotence, VasculogenicMaleMiddle AgedPenile ErectionProspective StudiesSeverity of Illness IndexSpectrophotometrySurveys and QuestionnairesTime FactorsARG2 protein, humanArginaseBiomarkersErectile dysfunction, IIEF-5Serum Arginase IISeverity of erectile dysfunctionVasculogenic erectile dysfunction

Identifiers

PMID29956132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.